Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Inventory (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 9 years of Inventory data on record, last reported at $32.8 million in Q4 2025.

  • For Q4 2025, Inventory rose 8849.18% year-over-year to $32.8 million; the TTM value through Dec 2025 reached $32.8 million, up 8849.18%, while the annual FY2025 figure was $32.8 million, 8849.18% up from the prior year.
  • Inventory reached $32.8 million in Q4 2025 per SNDX's latest filing, up from $25.0 million in the prior quarter.
  • Across five years, Inventory topped out at $32.8 million in Q4 2025 and bottomed at $22000.0 in Q2 2021.
  • Average Inventory over 3 years is $13.4 million, with a median of $11.2 million recorded in 2025.
  • The widest YoY moves for Inventory: up 8849.18% in 2025, down 8849.18% in 2025.
  • A 3-year view of Inventory shows it stood at $22000.0 in 2021, then soared by 1563.64% to $366000.0 in 2024, then skyrocketed by 8849.18% to $32.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $32.8 million in Q4 2025, $25.0 million in Q3 2025, and $17.7 million in Q2 2025.